Symbols / TENX Stock $12.17 +1.84% Tenax Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
TENX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Christopher T. Giordano
Exch · Country NCM · United States
Market Cap 313.69M
Enterprise Value 503.52M
Income -52.60M
Sales —
FCF (ttm) -18.44M
Book/sh 2.29
Cash/sh 1.94
Employees 14
Insider 10d —
IPO Apr 04, 1994
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -8.32
PEG 1.44
P/S —
P/B 5.32
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 13.63
Current Ratio 14.56
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.34
EPS next Y -1.46
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-10
Earnings (prior) 2026-03-10
ROA -35.08%
ROE -55.64%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 25.78M
Shs Float 21.99M
Insider Own 0.07%
Instit Own 45.58%
Short Float 2.87%
Short Ratio 1.25
Short Interest 730.70K
52W High 18.38
vs 52W High -33.79%
52W Low 5.34
vs 52W Low 127.90%
Beta 1.00
Impl. Vol. 1.42%
Rel Volume 1.01
Avg Volume 498.77K
Volume 505.06K
Target (mean) $29.71
Tgt Median $30.00
Tgt Low $20.00
Tgt High $36.00
# Analysts 7
Recom Strong_buy
Prev Close $11.95
Price $12.17
Change 1.84%
About

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$29.71
Mean price target
2. Current target
$12.17
Latest analyst target
3. DCF / Fair value
$-12.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$12.17
Low
$20.00
High
$36.00
Mean
$29.71

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-17 init Cantor Fitzgerald — → Overweight $35
2026-03-16 main Guggenheim Buy → Buy $34
2025-12-17 main Guggenheim Buy → Buy $25
2025-09-08 init Piper Sandler — → Overweight $20
2025-08-14 main Guggenheim Buy → Buy $14
2024-10-24 init Leerink Partners — → Outperform $16
2024-02-20 reit Roth MKM Buy → Buy $30
News
RSS: Latest TENX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-30 MCGAULEY THOMAS A Chief Financial Officer — 50,000 $12.51 $625,500
2025-12-09 RICH STUART Officer and Director — 5,000 $10.10 $50,792
2025-12-04 RICH STUART Officer and Director — 5,000 $9.01 $45,622
2025-11-20 GIORDANO CHRISTOPHER THOMAS Chief Executive Officer — 2,605 $7.51 $20,000
2025-11-18 ALMENOFF JUNE SHERIE Director — 1,993 $7.15 $14,945
2025-11-18 ALMENOFF JUNE SHERIE Director — 1,993 $7.15 $14,945
2025-11-17 MCGAULEY THOMAS A Chief Financial Officer — 8,000 $7.23 $58,164
2024-08-08 PROEHL GERALD T Director — 1,666 $4.07 $6,781
2024-08-08 DAVIDSON MICHAEL H Director — 2,500 $4.07 $10,175
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
56.38
+189.24%
19.49
+136.75%
8.23
-25.50%
11.05
Research And Development
32.67
+157.08%
12.71
+293.59%
3.23
-39.95%
5.38
Selling General And Administration
23.71
+249.49%
6.79
+35.56%
5.00
-11.81%
5.68
General And Administrative Expense
23.71
+249.49%
6.79
+35.56%
5.00
-11.81%
5.68
Salaries And Wages
17.60
+468.38%
3.10
+42.21%
2.18
-8.16%
2.37
Other Gand A
6.12
+65.79%
3.69
+30.45%
2.83
-14.43%
3.30
Total Expenses
56.38
+189.24%
19.49
+136.75%
8.23
-25.50%
11.05
Operating Income
-56.38
-189.24%
-19.49
-136.75%
-8.23
+25.50%
-11.05
Total Operating Income As Reported
-56.38
-189.24%
-19.49
-136.75%
-8.23
+25.50%
-11.05
EBITDA
-52.60
-199.21%
-17.58
-128.92%
-7.68
+29.74%
-10.93
Normalized EBITDA
-52.60
-199.21%
-17.58
-128.92%
-7.68
+29.74%
-10.93
Reconciled Depreciation
—
0.00
-100.00%
0.01
-92.94%
0.11
EBIT
-52.60
-199.21%
-17.58
-128.68%
-7.69
+30.39%
-11.04
Net Income
-52.60
-198.82%
-17.60
-128.27%
-7.71
+30.20%
-11.05
Pretax Income
-52.60
-198.82%
-17.60
-128.27%
-7.71
+30.20%
-11.05
Net Non Operating Interest Income Expense
3.82
+101.96%
1.89
+311.09%
0.46
+10453.36%
-0.00
Interest Expense Non Operating
0.00
-100.00%
0.02
-4.17%
0.02
+440.18%
0.00
Net Interest Income
3.82
+101.96%
1.89
+311.09%
0.46
+10453.36%
-0.00
Interest Expense
0.00
-100.00%
0.02
-4.17%
0.02
+440.18%
0.00
Interest Income Non Operating
3.82
+99.53%
1.91
+295.45%
0.48
—
Interest Income
3.82
+99.53%
1.91
+295.45%
0.48
—
Other Income Expense
-0.03
-3400.00%
0.00
-98.41%
0.06
+585.45%
0.01
Other Non Operating Income Expenses
-0.03
-3400.00%
0.00
-98.41%
0.06
+585.45%
0.01
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-52.60
-198.82%
-17.60
-128.27%
-7.71
+30.20%
-11.05
Net Income From Continuing Operation Net Minority Interest
-52.60
-198.82%
-17.60
-128.27%
-7.71
+30.20%
-11.05
Net Income From Continuing And Discontinued Operation
-52.60
-198.82%
-17.60
-128.27%
-7.71
+30.20%
-11.05
Net Income Continuous Operations
-52.60
-198.82%
-17.60
-128.27%
-7.71
+30.20%
-11.05
Normalized Income
-52.60
-198.82%
-17.60
-128.27%
-7.71
+30.20%
-11.05
Net Income Common Stockholders
-52.60
-198.82%
-17.60
-128.27%
-7.71
+30.20%
-11.05
Diluted EPS
-1.34
-16.52%
-1.15
+96.30%
-31.04
+94.83%
-600.71
Basic EPS
-1.34
-16.52%
-1.15
+96.30%
-31.04
+94.83%
-600.71
Basic Average Shares
39.22
+156.80%
15.27
+6046.87%
0.25
+1250.92%
0.02
Diluted Average Shares
39.22
+156.80%
15.27
+6046.87%
0.25
+1250.92%
0.02
Diluted NI Availto Com Stockholders
-52.60
-198.82%
-17.60
-128.27%
-7.71
+30.20%
-11.05
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
104.23
+7.80%
96.69
+727.44%
11.69
+243.20%
3.40
Current Assets
104.23
+7.80%
96.69
+727.51%
11.68
+264.16%
3.21
Cash Cash Equivalents And Short Term Investments
—
—
9.79
—
Cash And Cash Equivalents
97.56
+2.86%
94.85
+868.66%
9.79
+361.09%
2.12
Other Short Term Investments
—
—
—
—
Prepaid Assets
5.64
+218.63%
1.77
+7.99%
1.64
+121.94%
0.74
Other Current Assets
1.02
+1492.19%
0.06
-74.60%
0.25
-27.14%
0.35
Total Non Current Assets
0.00
0.00
-100.00%
0.00
-99.49%
0.20
Net PPE
—
—
0.00
-100.00%
0.19
Gross PPE
—
—
0.00
-100.00%
0.19
Other Properties
—
—
—
0.19
Other Non Current Assets
—
—
0.00
-89.53%
0.01
Total Liabilities Net Minority Interest
7.16
+52.48%
4.69
+30.83%
3.59
+87.61%
1.91
Current Liabilities
7.16
+52.48%
4.69
+30.83%
3.59
+94.13%
1.85
Payables And Accrued Expenses
6.26
+86.42%
3.36
+45.32%
2.31
+232.94%
0.69
Payables
6.04
+91.35%
3.16
+52.29%
2.07
+362.28%
0.45
Accounts Payable
6.04
+91.35%
3.16
+52.29%
2.07
+362.28%
0.45
Current Accrued Expenses
0.22
+8.50%
0.20
-15.61%
0.24
-3.42%
0.25
Pensionand Other Post Retirement Benefit Plans Current
0.90
-32.78%
1.34
+72.39%
0.78
+88.90%
0.41
Current Debt And Capital Lease Obligation
—
—
0.50
-32.63%
0.74
Current Debt
—
—
0.50
-19.75%
0.62
Other Current Borrowings
—
—
—
0.62
Current Capital Lease Obligation
—
—
0.00
-100.00%
0.12
Other Current Liabilities
—
—
0.00
—
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
-100.00%
0.06
Long Term Debt And Capital Lease Obligation
—
—
0.00
-100.00%
0.06
Long Term Capital Lease Obligation
—
—
0.00
-100.00%
0.06
Stockholders Equity
97.07
+5.52%
91.99
+1036.00%
8.10
+442.49%
1.49
Common Stock Equity
97.07
+5.52%
91.99
+1036.00%
8.10
+442.49%
1.49
Capital Stock
0.00
0.00
0.00
-100.00%
0.00
Common Stock
0.00
0.00
0.00
-100.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
9.31
+172.27%
3.42
+1046.87%
0.30
+941.23%
0.03
Ordinary Shares Number
9.31
+172.27%
3.42
+1046.87%
0.30
+941.23%
0.03
Additional Paid In Capital
464.52
+14.18%
406.85
+33.24%
305.35
+4.92%
291.03
Retained Earnings
-367.45
-16.71%
-314.86
-5.92%
-297.25
-2.66%
-289.54
Gains Losses Not Affecting Retained Earnings
—
—
—
—
Total Equity Gross Minority Interest
97.07
+5.52%
91.99
+1036.00%
8.10
+442.49%
1.49
Total Capitalization
97.07
+5.52%
91.99
+1036.00%
8.10
+442.49%
1.49
Working Capital
97.07
+5.52%
91.99
+1036.14%
8.10
+495.06%
1.36
Invested Capital
97.07
+5.52%
91.99
+969.81%
8.60
+306.18%
2.12
Total Debt
—
—
0.50
-37.99%
0.81
Capital Lease Obligations
—
—
0.00
-100.00%
0.18
Net Tangible Assets
97.07
+5.52%
91.99
+1036.00%
8.10
+442.49%
1.49
Tangible Book Value
97.07
+5.52%
91.99
+1036.00%
8.10
+442.49%
1.49
Current Notes Payable
—
0.00
-100.00%
0.50
-19.75%
0.62
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-35.80
-141.71%
-14.81
-150.86%
-5.90
+48.16%
-11.39
Cash Flow From Continuing Operating Activities
-35.80
-141.71%
-14.81
-150.86%
-5.90
+48.16%
-11.39
Net Income From Continuing Operations
-52.60
-198.82%
-17.60
-128.27%
-7.71
+30.20%
-11.05
Depreciation Amortization Depletion
—
0.00
-100.00%
0.01
-92.94%
0.11
Depreciation
—
—
0.01
-93.32%
0.11
Depreciation And Amortization
—
0.00
-100.00%
0.01
-92.94%
0.11
Other Non Cash Items
—
0.02
-4.17%
0.02
+440.18%
0.00
Stock Based Compensation
19.16
+1603.38%
1.12
+489.01%
0.19
—
Operating Gains Losses
—
—
0.00
-99.72%
0.36
Gain Loss On Investment Securities
—
—
0.19
-47.76%
0.37
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.00
+134.47%
-0.00
Change In Working Capital
-2.36
-243.88%
1.64
+3.79%
1.58
+292.85%
-0.82
Change In Receivables
—
0.06
+118.95%
-0.31
+14.17%
-0.36
Changes In Account Receivables
—
0.06
+118.95%
-0.31
+14.17%
-0.36
Change In Prepaid Assets
-4.83
-8422.41%
0.06
—
—
Change In Payables And Accrued Expense
2.46
+55.39%
1.58
-16.09%
1.89
+647.61%
-0.34
Change In Accrued Expense
-0.42
-180.50%
0.52
+120.68%
0.24
—
Change In Payable
2.88
+171.56%
1.06
-35.71%
1.65
—
Change In Account Payable
2.88
+171.56%
1.06
-35.71%
1.65
—
Change In Other Current Liabilities
—
—
0.00
+100.00%
-0.12
Investing Cash Flow
—
0.00
-100.00%
0.00
+229.14%
-0.00
Cash Flow From Continuing Investing Activities
—
0.00
-100.00%
0.00
+229.14%
-0.00
Net PPE Purchase And Sale
—
0.00
-100.00%
0.00
+229.14%
-0.00
Purchase Of PPE
—
—
—
-0.00
Sale Of PPE
—
0.00
-100.00%
0.00
—
Capital Expenditure
—
—
—
-0.00
Net Investment Purchase And Sale
—
—
—
0.00
Purchase Of Investment
—
—
—
0.00
Sale Of Investment
—
—
—
0.00
Financing Cash Flow
38.51
-61.44%
99.87
+636.02%
13.57
+71.10%
7.93
Cash Flow From Continuing Financing Activities
38.51
-61.44%
99.87
+636.02%
13.57
+71.10%
7.93
Net Issuance Payments Of Debt
0.00
+100.00%
-0.50
+19.71%
-0.62
0.00
Issuance Of Debt
—
—
—
0.62
Repayment Of Debt
0.00
+100.00%
-0.50
+19.71%
-0.62
0.00
Long Term Debt Issuance
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Short Term Debt Issuance
—
—
—
0.62
Short Term Debt Payments
0.00
+100.00%
-0.50
+19.71%
-0.62
0.00
Net Short Term Debt Issuance
0.00
+100.00%
-0.50
+19.71%
-0.62
0.00
Net Common Stock Issuance
—
—
—
—
Proceeds From Stock Option Exercised
38.51
-61.63%
100.37
+607.19%
14.19
+78.96%
7.93
Changes In Cash
2.71
-96.81%
85.06
+1009.27%
7.67
+321.60%
-3.46
Beginning Cash Position
94.85
+868.66%
9.79
+361.02%
2.12
-61.96%
5.58
End Cash Position
97.56
+2.86%
94.85
+868.66%
9.79
+361.09%
2.12
Free Cash Flow
-35.80
-141.71%
-14.81
-150.86%
-5.90
+48.17%
-11.39
Interest Paid Supplemental Data
0.00
-100.00%
0.02
-4.17%
0.02
—
Amortization Of Securities
—
—
—
0.00
Common Stock Issuance
—
—
—
—
Issuance Of Capital Stock
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category